24-Hour Efficacy of Travoprost/Timolol BAK-Free Versus Latanoprost/Timolol Fixed Combinations in Patients Insufficiently Controlled with Latanoprost

Konstas, Anastasios G. P.; Voudouragkaki, Irini C.; Boboridis, Kostas; Haidich, Anna‐Bettina; Paschalinou, Eleni; Giannopoulos, Theodoros; Dragoumis, Nikolaos; Makridis, A. K.; Kahook, Malik Y.

doi:10.1007/s12325-014-0125-9

Cited by 22 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, there is limited controlled evidence pertaining to the health of the ocular surface with chronic combined antiglaucoma therapy [33]. In the present study we employed three easy-to-perform clinical ocular surface metrics: the TFBUT, corneal staining, and the Schirmer test.…”

Section: Discussionmentioning

confidence: 99%

24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

IntroductionThe aim of the present study was to evaluate the 24-h efficacy, tolerability, and ocular surface health with preservative-free (PF) tafluprost and a PF triple drug regimen comprising tafluprost and dorzolamide/timolol fixed combination (DTFC) in open-angle glaucoma patients who were insufficiently controlled with preserved branded or generic latanoprost monotherapy and who exhibited signs or symptoms of ocular surface disease (OSD).MethodsProspective, observer-masked, crossover, comparison. Eligible consecutive open-angle glaucoma patients were randomized to either PF tafluprost or the triple PF regimen for 3 months. They were then crossed over to the opposite therapy for another 3 months. At the end of the latanoprost run-in period and after each PF treatment period, patients underwent habitual 24-h intraocular pressure (IOP) monitoring with Goldmann tonometry in the sitting position (at 10:00, 14:00, 18:00, and 22:00) and Perkins tonometry in the supine position (at 02:00 and 06:00). Tolerability and selected ocular surface parameters were evaluated at baseline and the end of each treatment period.ResultsForty-three open-angle glaucoma patients completed the trial. Mean 24-h IOP on preserved latanoprost was 22.2 ± 3.9 mmHg. Compared with latanoprost monotherapy, PF tafluprost obtained a greater reduction in mean, peak, and fluctuation of 24-h IOP including the 02:00 and 06:00 time points (P < 0.05). With the exception of 24-h fluctuation, the triple PF regimen provided significantly lower IOP parameters than latanoprost or PF tafluprost (P < 0.001). Finally, PF tafluprost therapy displayed significantly improved tear film break-up times (6.7 vs 6.0 s), corneal staining (1.3 vs 2.2), and Schirmer I test results (9.1 vs 8.2 mm) compared with the preserved latanoprost baseline (all P < 0.01). The triple PF regimen demonstrated similar tear film break-up times (6.1 vs 6.0 s) and Schirmer I test results (8.2 vs 8.2 mm) to latanoprost, but revealed a significant improvement in the corneal stain test (1.7 vs 2.2; P < 0.001).ConclusionsIn this trial PF tafluprost therapy provided statistically greater 24-h efficacy and improved tolerability compared with preserved latanoprost. The combination of PF tafluprost and PF dorzolamide/timolol fixed combination was statistically and clinically more efficacious than both monotherapies and demonstrated similar ocular surface characteristics to preserved latanoprost monotherapy.Trial registrationClinicalTrials.gov (NCT02802137).FundingSanten.

show abstract

Section: Discussionmentioning

confidence: 99%

24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The IOP-lowering efficacy of TTFC and TRAVþTIM has been demonstrated previously. [28][29][30][31] IOP change from baseline was not a primary outcome of the current study; however, both treatment regimens effectively reduced IOP from baseline. Both treatments were well tolerated, and no new safety concerns were identified with either treatment regimen.…”

Section: Discussionmentioning

confidence: 99%

Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial

Barnebey¹,

Robin

2017

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…It should also be noted that subsequent to the phase III studies a number of complete 24-h crossover comparison studies have been published with Xalacom ® , DuoTrav ® , and Ganfort ® (e.g., [35–38]). These studies could not be included in the current analysis; but their clinical relevance is emphasized, as they highlight the true overall efficacy of the products and have revealed a convincing separation between the products and prostaglandin constituents.…”

Section: Discussionmentioning

confidence: 99%

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products

Holló

Vuorinen²,

Tuominen

et al. 2014

Adv Ther

View full text Add to dashboard Cite

A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F2α analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduction with TAF/TIM in open-angle glaucoma and ocular hypertension is similar to that of other prostaglandin–timolol fixed-combination products. Patients with high IOP responded well to TAF/TIM with reductions of up to 40% (>13 mmHg) and beyond. Compared to previous controlled and double-masked clinical trials with DuoTrav® (Alcon, Fort Worth, USA) and Ganfort® (Allergan, Irvine, USA), TAF/TIM caused less superficial ocular side effects and less conjunctival hyperemia. Plausible explanations for the differences in side effects between the fixed-combination products are discussed.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-014-0151-7) contains supplementary material, which is available to authorized users.

show abstract

24-Hour Efficacy of Travoprost/Timolol BAK-Free Versus Latanoprost/Timolol Fixed Combinations in Patients Insufficiently Controlled with Latanoprost

Abstract: The mean 24-h IOP lowering of TTFC was statistically more significant compared to LTFC in patients insufficiently controlled with latanoprost monotherapy. Measurement of ocular surface health and tear film status favored the BAK-free TTFC compared to LTFC.

Cited by 22 publications

References 33 publications

24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy

24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy

Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products

Contact Info

Product

Resources

About